Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM–CAMPATH (± fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion
- 1 May 2001
- journal article
- clinical trial
- Published by Elsevier in Cytotherapy
- Vol. 3 (3) , 203-210
- https://doi.org/10.1080/146532401753174034
Abstract
We report our updated experience of allogeneic transplantation in lymphoproliferative disorders using a reduced-intensity conditioning regimen combining BEAM (plus fludarabine in three cases) with pretransplant CAMPATH. Post-transplant donor lymphocytes have been infused for persisting disease or relapse, and both chimerism and minimal residual disease have been monitored utilizing molecular techniques. Thirty patients with median age 47.6 years underwent allogeneic transplantation for relapsed or high-risk lymphoproliferative disease using HLA-identical (sibling n = 25, unrelated n = 2) or one antigen mismatched sibling donors (n = 3). Twenty-one had NHL, three had HD and six had CLL/PLL. Stem-cell source was PBSC (n = 24), BM (n = 5) or both (n = 1) with a median CD34 dose of 4.5 × 106/kg. GvHD prophylaxis was with CYA and MTX. Engraftment was prompt in the majority of patients, with a median of 15 days to both ANC < 0.5 and platelets < 20. There have been three transplant-related deaths secondary to viral pneumonitis or bacterial pneumonia. Seven patients developed Grade I–II acute GvHD posttransplant. Of 28 evaluable patients, 18 achieved a CR at assessment 2–3 months post-transplant and a further patient converted from PR to CR following DLI, to give an overall CR rate of 68%. Three patients had early progressive disease and six have relapsed from CR or progressed from PR (two of whom have achieved CR following DLI therapy). Overall survival is 67% and event-free survival 48% at 3 years. With a median follow-up of 1.3 years 57% of patients are currently alive and lymphoma-free. A molecular remission has been achieved in nine of 12 informative patients. These encouraging results show that this reduced-intensity conditioning regimen is effective, with a low-toxicity profile compared with conventional TBI-based conditioning, and certainly merits further evaluation in this setting.Keywords
This publication has 28 references indexed in Scilit:
- International Consensus Conference on High-Dose Therapy With Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the JuryJournal of Clinical Oncology, 1999
- Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998Bone Marrow Transplantation, 1998
- Comparison Between Conventional Salvage Therapy and High-Dose Therapy With Autografting for Recurrent or Refractory Hodgkin's DiseaseBlood, 1997
- Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.Journal of Clinical Oncology, 1996
- Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.Journal of Clinical Oncology, 1996
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995
- Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.Journal of Clinical Oncology, 1993
- Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialThe Lancet, 1993
- Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data.Journal of Clinical Oncology, 1992
- Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantationBlood, 1991